Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Midsize Japanese Pharmas Seen As Major Drivers Of Merger Mania

This article was originally published in PharmAsia News

Executive Summary

Midsize Japanese pharmaceuticals are seen as reaping most of the benefits of a global merger fever in the industry as foreign firms look to Japan for business opportunities. Japan does not expect to see a slowdown in the mergers-and-acquisition activity this year, following up on major merger activity of last year. An investment executive says midsize firms facing loss of patent protection for some of their drugs, plus government efforts to drive down the cost of drugs in Japan, will begin restructuring, including taking on M&As, to stay afloat and compete. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel